Status: Recruiting
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.
Participants needed: 220
Trial details
Phase: Phase 1, Phase 2Age: Up to 20Biological sex: AllType: InterventionalSponsor: Washington University School of MedicineUpdated: Mar 25, 2026Locations: 28
Eligibility criteria
Recipient age < 21 years [+5]
HIV positive [+2]